Current concepts in rational therapy for haemochromatosis

Crawford, D. H. G. and Halliday, J. W. (1991) Current concepts in rational therapy for haemochromatosis. Drugs, 41 6: 875-882. doi:10.2165/00003495-199141060-00005

Author Crawford, D. H. G.
Halliday, J. W.
Title Current concepts in rational therapy for haemochromatosis
Journal name Drugs   Check publisher's open access policy
ISSN 0012-6667
Publication date 1991-06-01
Year available 1991
Sub-type Article (original research)
DOI 10.2165/00003495-199141060-00005
Open Access Status Not Open Access
Volume 41
Issue 6
Start page 875
End page 882
Total pages 8
Place of publication Auckland, New Zealand
Publisher Adis International
Language eng
Abstract Genetic haemochromatosis is characterised by an inappropriately high rate of iron absorption by the small intestine. The disease is transmitted as an autosomal recessive condition. The gene frequency in the Caucasian population is approximately 1 in 20 and the disease frequency is 1 in 400. Excessive iron deposition occurs in the liver, pancreas, heart, pituitary and joints and hepatic iron concentrations above approximately 400 μmol/g dry weight are always associated with fibrosis and usually with cirrhosis and progressive liver failure. Accurate diagnosis depends upon the demonstration of elevated hepatic iron stores. An hepatic iron index [hepatic iron concentration (in μmol/g dry weight) divided by patient age] of greater than 2.0 distinguishes homozygous subjects from the other conditions in which slight increases in hepatic iron concentration may occur, e.g. in a subject heterozygous for haemochromatosis or alcoholic liver disease. If cirrhosis is present, patients are at a high risk of developing hepatocellular carcinoma. Therefore, they should undergo regular abdominal ultrasound and α-fetoprotein estimation. In the absence of cirrhosis, phlebotomy restores life expectancy to normal. Venesection should be continued until all excess iron stores are removed as judged by failure of a rise in haemoglobin concentration on cessation of phlebotomy. Screening of first degree relatives should commence from a young age (e.g. 10 years). If serum ferritin or tranferrin saturation are abnormal, liver biopsy should be undertaken. HLA typing of the family allows for the identification of those siblings who are most likely to develop the disease. Secondary iron overload is often multifactorial in origin. Iron chelation therapy with subcutaneous deferoxamine (desferrioxamine) should only commence after careful consideration of the potential benefits in each individual patient.
Keyword Pharmacology & Pharmacy
Pharmacology & Pharmacy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 10 Mar 2011, 01:44:30 EST